Filip Janku, the Chief Medical Officer of $GLUE, sold 5,407 shares of the company on 06-30-2026 for an estimated $132,471. We received data on the trade from a recent SEC filing. This was a sale of approximately 8.2% of their shares of this class of stock. Following this trade, they now own 60,612 shares of this class of $GLUE stock.
$GLUE Insider Trading Activity
$GLUE insiders have traded $GLUE stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $GLUE stock by insiders over the last 6 months:
- FILIP JANKU (Chief Medical Officer) has made 0 purchases and 5 sales selling 62,441 shares for an estimated $1,331,535.
- MARKUS WARMUTH (President & CEO) has made 0 purchases and 6 sales selling 24,399 shares for an estimated $470,918.
- EDMUND DUNN (Principal Accounting Officer) has made 0 purchases and 3 sales selling 25,839 shares for an estimated $467,382.
- SHARON TOWNSON (Chief Scientific Officer) has made 0 purchases and 3 sales selling 12,000 shares for an estimated $236,220.
- ANTHONY M. MANNING sold 10,000 shares for an estimated $231,100
- JENNIFER CHAMPOUX (Chief Operating Officer) has made 0 purchases and 4 sales selling 8,702 shares for an estimated $169,688.
- PHILIP NICKSON (Chief Business & Legal Officer) sold 5,845 shares for an estimated $103,412
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$GLUE Hedge Fund Activity
We have seen 128 institutional investors add shares of $GLUE stock to their portfolio, and 66 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP added 2,828,465 shares (+365.0%) to their portfolio in Q1 2026, for an estimated $46,528,249
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,601,284 shares (+31.3%) to their portfolio in Q1 2026, for an estimated $26,341,121
- AMERICAN CENTURY COMPANIES INC added 1,480,028 shares (+111.3%) to their portfolio in Q1 2026, for an estimated $24,346,460
- BLACKROCK, INC. added 1,456,523 shares (+34.8%) to their portfolio in Q1 2026, for an estimated $23,959,803
- BELLEVUE GROUP AG added 1,250,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $20,562,500
- STATE STREET CORP added 1,246,500 shares (+59.1%) to their portfolio in Q1 2026, for an estimated $20,504,925
- VERSANT VENTURE MANAGEMENT, LLC removed 1,201,907 shares (-27.4%) from their portfolio in Q1 2026, for an estimated $19,771,370
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$GLUE Price Targets
Multiple analysts have issued price targets for $GLUE recently. We have seen 4 analysts offer price targets for $GLUE in the last 6 months, with a median target of $33.0.
Here are some recent targets:
- Michael Schmidt from Guggenheim set a target price of $35.0 on 06/30/2026
- Brian Cheng from JP Morgan set a target price of $31.0 on 05/11/2026
- Derek Archila from Wells Fargo set a target price of $29.0 on 03/18/2026
- Edward Tenthoff from Piper Sandler set a target price of $37.0 on 01/14/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
